lorazepam has been researched along with sch 16134 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bixler, EO; Jacoby, JA; Kales, A; Kales, JD; Soldatos, CR | 1 |
| Ellinwood, EH; Heatherly, DG; Nikaido, AM | 1 |
| Wettstein, JG | 1 |
| Carskadon, M; Dement, W; Seidel, W | 1 |
2 review(s) available for lorazepam and sch 16134
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rebound insomnia and elimination half-life: assessment of individual subject response.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Flurazepam; Half-Life; Humans; Lorazepam; Midazolam; Middle Aged; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Time Factors; Triazolam | 1985 |
1 trial(s) available for lorazepam and sch 16134
| Article | Year |
|---|---|
Rebound insomnia and elimination half-life: assessment of individual subject response.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Flurazepam; Half-Life; Humans; Lorazepam; Midazolam; Middle Aged; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Time Factors; Triazolam | 1985 |
4 other study(ies) available for lorazepam and sch 16134
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Comparative pharmacodynamics of benzodiazepines.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Diazepam; Humans; Kinetics; Lorazepam; Male; Psychomotor Performance; Triazolam | 1987 |
Effects of the novel benzodiazepine agonist quazepam on suppressed behavior of monkeys.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Benzodiazepines; Conditioning, Operant; Dose-Response Relationship, Drug; Flumazenil; Lorazepam; Male; Quinazolines; Reinforcement Schedule; Saimiri | 1988 |
Daytime alertness, insomnia, and benzodiazepines.
Topics: Adult; Anti-Anxiety Agents; Arousal; Benzodiazepines; Double-Blind Method; Flurazepam; Humans; Lorazepam; Male; Oxazepam; Sleep Deprivation; Sleep Initiation and Maintenance Disorders; Sleep Stages; Triazolam; Wakefulness | 1982 |